ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR059

High FGF-23 Is Associated with Coronary Calcification Only in Patients with High Adiponectin: From the KNOW-CKD Study

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 303 CKD: Epidemiology, Outcomes - Cardiovascular


  • Hyun, Young Youl, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)
  • Oh, Kook-Hwan, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Ahn, Curie, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Kim, Yong-Soo, The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)
  • Yoo, Tae-Hyun, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Kim, Soo Wan, Chonnam National University Medical School, Dongku, Korea (the Republic of)
  • Kim, Yeong Hoon, Inje University Medical School, Busan, Korea (the Republic of)

Group or Team Name

  • KNOW-CKD Study Group

Both FGF-23 and coronary artery calcification (CAC) are known as predictors of high cardiovascular and all-cause mortality. However, previous studies on the association between FGF-23 and CAC were inconclusive. Recently, it has been shown that adiponectin modulates renal handling of phosphate and calcium, important factors in vascular calcification. We hypothesized that adiponectin play a role in the effect of FGF-23 on CAC, and explored whether this association between FGF-23 and CAC is modified by serum adiponectin level in CKD patients.


This cross-sectional study analyzed 1,153 predialysis CKD patients from the KNOW-CKD cohort who measured coronary artery calcium scores (CACS), serum FGF-23 and serum adiponectin. Participants were divided into three groups according to their FGF-23 levels as follows: low <5.0 RU/ml, middle =5.0-29.9 RU/ml, and high ≥30.0 RU/ml. We evaluated the association between FGF-23 and CACS by multivariate Tobit regression and multivariate logistic regression in each group with lower half and upper half of adiponectin.


Median [interquartile range] CACS were not different between low and high adiponectin group (2.0 [0.0-91.8] vs 0.4 [0.0-103.5], P=0.536). The CACS ratio comparing the high FGF-23 to the low FGF-23 was significantly increased in high adiponectin group, but not in low adiponectin group [3.25 (1.53-6.91) vs 1.07 (0.50-2.29), P for interaction=0.029). Similarly, the ORs for CAC in the high FGF-23 group compared to the low group were significantly increased only in the high adiponectin group (Table).


High serum FGF-23 was associated with CAC only in CKD patients with high adiponectin, but not in those with low adiponectin. Further studies are warranted to verify the role of adiponectin in FGF-23-related coronary calcification.

ORs (95% CI) for CAC in different FGF-23 groups according to adiponectin level
 Low adiponectinHigh adiponectinP for interaction
CAC definitionlow (n=252)
middle (n=202)
high (n=123)
low (n=181)
middle (n=206)
high (n=189)
CACS>0reference0.88 (0.54-1.45)
1.11 (0.62-2.02)
reference1.11 (0.67-1.87)
2.15 (1.21-3.80)
CACS≥100reference0.98 (0.56-1.74)
0.88 (0.45-1.73)
reference1.62 (0.88-2.98)
2.34 (1.24-4.42)
CACS≥400reference1.25 (0.63-2.48)
0.68 (0.29-1.55)
reference1.65 (0.74-3.67)
4.03 (1.82-8.91)

Adjusted for age, sex, BMI, hypertension, diabetes, dyslipidemia, current smoking, eGFR, hsCRP, urine protein to creatinine ratio, calcium, phosphorus, ALP, 25-OH-vit D, intact PTH


  • Government Support - Non-U.S.